Advertisement
MedImmune
Subscribe to MedImmune

The Lead

MedImmune and Advaxis Partner on Immuno-Oncology Combination Clinical Trial

July 22, 2014 8:20 am | News | Comments

AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a clinical trial collaboration with Advaxis, Inc., a US-based biotechnology company developing cancer immunotherapies.    

Incyte and MedImmune to Collaborate on Immuno-Oncology Combination Clinical Trial

May 14, 2014 8:06 am | News | Comments

The Phase I/II oncology study will evaluate the efficacy and safety of MedImmune’s...

MedImmune and Immunocore to Develop Novel Cancer Therapies

January 8, 2014 8:25 am | News | Comments

AstraZeneca today announced that MedImmune, its global biologics research and development arm,...

AstraZeneca's MedImmune Acquires Spirogen - Boosts Antibody-Drug Conjugate Capability

October 15, 2013 8:51 am | News | Comments

AstraZeneca today announced that MedImmune, its global biologics research and development arm,...

View Sample

FREE Email Newsletter

MedImmune Strengthens Immune-Mediated Cancer Therapy Portfolio with Acquisition of Amplimmune

August 26, 2013 9:04 am | News | Comments

AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a definitive agreement to acquire Amplimmune, a privately-held, Maryland, US-based biologics company focused on developing novel therapeutics in cancer immunology.

MedImmune, AstraZeneca’s Biologics Arm, and NGM Biopharmaceuticals Announce Agreement to Discover and Develop Therapies for Diabetes and Obesity

June 17, 2013 8:06 am | News | Comments

AstraZeneca today announced that MedImmune, its global biologics research and development arm, and NGM Biopharmaceuticals, Inc. have entered into an exclusive agreement to discover, develop and commercialize novel therapeutics from NGM’s enteroendocrine cell (EEC) program for the treatment of type 2 diabetes and obesity.

MedImmune, AstraZeneca’s Biologics Unit, Acquires AlphaCore Pharma

April 3, 2013 8:08 am | News | Comments

AstraZeneca today announced that MedImmune, its global biologics research and development unit, has acquired AlphaCore Pharma, an Ann Arbor, Michigan-based biotechnology company focused on the development of ACP-501, a recombinant human lecithin-cholesterol acyltransferase (LCAT) enzyme.

Advertisement

MedImmune In-Licenses Cancer Immunotherapy Tremelimumab from Pfizer

October 3, 2011 4:11 am | News | Comments

MedImmune, the global biologics arm of AstraZeneca, today announced execution of an in-licensing agreement with Pfizer Inc for tremelimumab (CP-675,206), a CTLA-4 monoclonal antibody.

U.S. Approves Flu Vaccine for Coming Season

July 18, 2011 1:01 pm | News | Comments

The U.S. Food and Drug Administration said Monday it has approved the new flu vaccine for the season beginning this year.

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading